Nature Genetics Study Validates Seer's Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery

GlobeNewsWire • Dec 1, 2025

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale

GlobeNewsWire • Nov 7, 2025

Seer, Inc. (SEER) Q3 2025 Earnings Call Transcript

Seer, Inc. ( SEER ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Kelly Gura Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors David Horn - President,Treasurer & CFO Conference Call Participants William Ruby - TD Cowen, Research Division Presentation Operator Good day, and welcome to the Seer Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Seeking Alpha • Nov 7, 2025

Seer Reports Third Quarter 2025 Financial Results

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 6, 2025

Seer to Participate in Upcoming November Investor Conferences

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FLHosting 1x1 meetings on Wednesday, November 12th Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on Thursday, November 20th at 4:00 p.m.

GlobeNewsWire • Oct 29, 2025

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire • Oct 16, 2025

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers

GlobeNewsWire • Oct 10, 2025

Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Seer, Inc. (NASDAQ:SEER ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Omid Farokhzad - Founder, CEO, & Chair of the Board of Directors Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley.

Seeking Alpha • Sep 9, 2025

Seer Appoints Isaac Ro to its Board of Directors

REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors.

GlobeNewsWire • Sep 2, 2025

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.

GlobeNewsWire • Aug 26, 2025